At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
In Brief
A Phase 3 clinical trial evaluating Ombitasvir/paritaprevir/ritonavir, Dasabuvir, and 6 other interventions for Chronic Hepatitis C Infection. Completed, enrolled 64 participants across 21 sites in 5 countries.
Detailed Summary
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.
Study Details
Timeline
Interventions
Film-coated tablet for oral use
Film-coated tablet for oral use
Film-coated tablet for oral use
Film-coated tablet for oral use
Film-coated tablet for oral use
Film-coated tablet for oral use
Film-coated tablet for oral use
Oral solution